SCHEMBL3788673

SCHEMBL3788673

CNc1cccc(-c2ccc(N)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.52
CYP3A4 P08684 4/20 0.48
TDP1 Q9NUW8 2/20 0.48
HSD17B10 Q99714 1/20 0.48
SYK P43405 1/20 0.44
ALDH1A1 P00352 2/20 0.44
TP53 P04637 1/20 0.44
MAOA P21397 1/20 0.43
HTR6 P50406 2/20 0.43
MAP4K4 O95819 1/20 0.43
BRD4 O60885 1/20 0.41
MGLL Q99685 1/20 0.40
TSHR P16473 1/20 0.39
MAPT P10636 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX12 P18054 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28488286 0.89 TSHR (0.48) CYP3A4BRD4MGLLTSHRMAPT
SCHEMBL5041729 0.86 MAP4K4 (0.58) CYP3A4TDP1SYKALDH1A1MAOA
SCHEMBL1038467 0.83 TSHR (0.59) SYKALDH1A1MAOABRD4MGLL
SCHEMBL30288275 0.83 TSHR (0.59) SYKALDH1A1MAOABRD4MGLL
SCHEMBL16285571 0.82 MAPT (0.44) CYP3A4ALDH1A1BRD4MGLLTSHR
SCHEMBL23576809 0.82 NPC1 (0.42) BRD4MGLLTSHRMAPTCYP17A1
SCHEMBL16285564 0.81 MAPT (0.43) CYP3A4ALDH1A1TP53BRD4MGLL
SCHEMBL16270804 0.80 CNR1 (0.50) TAAR1CYP3A4ALDH1A1BRD4MGLL
SCHEMBL3790176 0.80 MAOA (0.59) TAAR1CYP3A4MAOAMAP4K4CYP17A1
SCHEMBL7806597 0.80 TAAR1 (0.52) TAAR1CYP3A4TDP1HSD17B10SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028978-A1 SUBSTITUTED BICYCLIC HCV INHIBITORS PRESIDIO PHARMACEUTICALS, INC. (US) 2012-02-02 US disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028978-A1 SUBSTITUTED BICYCLIC HCV INHIBITORS HAVCR2, LIPC, EIF2AK2 TAAR1 4139/4885CYP3A4 82/4885TDP1 4590/4885
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 TAAR1 1746/4885CYP3A4 177/4885TDP1 4196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.